China

Expert consensus on the use of omalizumab in chronic urticaria in China

173.

Zhao, Z.+, Cai, T., Chen, H., Chen, L., Chen, Y., Gao, X., Gao, X., Geng, S., Guo, Y., Hao, F., Hao, G., Hu, Y., Jin, H., Jin, Z., Li, C., Li, H., Li, J., Li, Y., Liang, Y., Liu, G., Liu, Q., Long, H., Ma, L., Shang, Y., Song, Y., Song, Z., Su, X., Sui, H., Sun, Q., Sun, Y., Tang, J., Tong, X., Wang, H., Wang, G., Wang, L., Wang, S., Xiang, L., Xiao, T., Xie, Z., Ye, L., Yu, Y., Zhang, C., Zhang, L., Zhang, S., Zheng, R., Zhi, L., Zhou, W., Zou, Y., and Maurer, M.+: Expert consensus on the use of omalizumab in chronic urticaria in China. World Allergy Organ. J. 2021: 14; e100610. IF: 5.52

r.173

Expert consensus on the use of omalizumab in chronic urticaria in China Read More »